Vimarsana
Biggest News Aggregation in the World

Continued Treatment News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Continued Treatment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Continued Treatment Today - Breaking & Trending Today

Investegate |Centessa Pharmaceuticals plc Announcements | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia - Vimarsana News

Investegate |Centessa Pharmaceuticals plc Announcements | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

Published: December 11, 2022

Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

Source: investegate.co.uk
Related Topics:
United StatesCity OfUnited KingdomTrevor Baglin MedscKristenk SheppardAmerican Society Of HematologyExchange CommissionDevelopment Of CentessaSafety Review GroupCentessa PharmaceuticalsCentessa Pharmaceuticals Announces AdditionalContinued Treatment DataOpen Label ExtensionAmerican SocietyAnnual MeetingSaurabh SahaChief Executive OfficerStudy PeriodSingle Ascending DoseContinued TreatmentTrevor Baglin Medscd PhdVice PresidentGlobal HeadAnnual ReportQuarterly Reports
Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia - Vimarsana News

Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia

Published: December 10, 2022

Oral presentation at American Society of Hematology (ASH) Annual Meeting highlights continued favorable safety and tolerability profile and sustained long-term efficacy results for SerpinPC: 93%

Source: finanznachrichten.de
Related Topics:
United StatesCity OfUnited KingdomTrevor Baglin MedscKristenk SheppardAmerican Society Of HematologyExchange CommissionDevelopment Of CentessaSafety Review GroupCentessa PharmaceuticalsAmerican SocietyAnnual MeetingSaurabh SahaChief Executive OfficerAfter PartContinued TreatmentTrevor Baglin Medscd PhdVice PresidentGlobal HeadAnnual ReportQuarterly Reports